Qube Research & Technologies (QRT)
VIRX

Qube Research & Technologies (QRT)’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed -$1 – 4305
2024
Q2 		$1 Hold
2
– – ﹤0.01% 3716
2024
Q1 		$2 Hold
2
– – ﹤0.01% 4373
2023
Q4 		$1 Hold
2
– – ﹤0.01% 4286
2023
Q3 		$2 Buy
+2
New +$3 ﹤0.01% 4021
2022
Q4 		– Sell
-27,252
Closed -$116K – 3095
2022
Q3 		$116K Sell
27,252
-3,664
-12% -$15.5K ﹤0.01% 1929
2022
Q2 		$120K Buy
+30,916
New +$88.1K ﹤0.01% 1875
2021
Q2 		– Sell
-10,326
Closed -$96K – 2893
2021
Q1 		$96K Buy
+10,326
New +$108K ﹤0.01% 1740

Other funds holding VIRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Qube Research & Technologies (QRT)'s VIRX Position: Q3 2024 in Review

Qube Research & Technologies (QRT) sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2024, closing a stake of 2 shares — an estimated $1 sold.

Qube Research & Technologies (QRT) first reported a position in VIRX in Q1 2021 and held it in 7 quarters. The position peaked at $120K in Q2 2022. 38 funds tracked by Wall St. Rank hold VIRX as of Q3 2024.

  • Qube Research & Technologies (QRT) reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 2 Viracta Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $1.
  • Qube Research & Technologies (QRT) first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • Qube Research & Technologies (QRT)'s Viracta Therapeutics, Inc. Common Stock position peaked at $120K in Q2 2022.
  • 38 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2024, filed 14 Nov 2024.